Clinical trial
Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate…
NCT00193271 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193271 |
|---|---|
| Title | Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer |
| Official title | Adjuvant Chemotherapy (Docetaxel and Estramustine Phosphate) for High Risk Localized Prostate Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Estramustine |
| Enrollment | 30 |
| Start date | Aug 1, 2004 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | May 3, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: